Acorda's novel approach to MS therapy attracts attention
This article was originally published in Scrip
Executive Summary
Amid speculation that Biogen Idec is looking to buy Acorda Therapeutics to gain access to its investigational oral multiple sclerosis candidate, fampridine-SR (4-aminopyridine), intriguing Phase III data demonstrating the drug's effects on patients' walking abilities were published in the February 28th issue of The Lancet.